TAAR1

Global Anxiety Disorders And Depression Treatment Market Analysis & Forecast 2024-2034: Market By Drug Class; By Indication; By Distribution Channel; and By Region - ResearchAndMarkets.com

Retrieved on: 
Thursday, February 8, 2024
Pharmaceutical, Health, Mental Health, Internet, Anxiety, DSM-IV codes, SAD, MDD, Research, PureTech Health, USD, Pharmacy, Social anxiety disorder, Prevalence, Patient, Distribution, GAD, PH94B, Ulotaront, FDA, Disorder, Tic disorder, PPD, Market, Depression, AbbVie, Zuranolone, MOA, Food, Commercialization, Therapy, TAAR1, Major depressive disorder, Sunovion, ADAA, Postpartum depression, NDA, Biogen, Conference, Pharmaceutical industry

The "Global Anxiety Disorders And Depression Treatment Market Analysis & Forecast 2024-2034: Market By Drug Class; By Indication; By Distribution Channel; and By Region" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Anxiety Disorders And Depression Treatment Market Analysis & Forecast 2024-2034: Market By Drug Class; By Indication; By Distribution Channel; and By Region" report has been added to ResearchAndMarkets.com's offering.
  • The global anxiety disorders and depression treatment market size was estimated to be USD 21.56 billion in 2023 and is expected to reach at USD 41.83 billion by 2034 with a CAGR of 6.21% during the forecast period 2024-2034.
  • Rising research & development activities for the development of innovative drugs for the treatment of anxiety & depression disorders is predicted to boost the market growth during the forecast period.
  • This application pertains to the use of cariprazine as an add-on treatment for individuals with major depressive disorder (MDD) who are already undergoing antidepressant therapy.

Demystifying a Key Receptor in Substance Use and Neuropsychiatric Disorders; Study sheds light on TAAR1, pointing to potential drug development opportunities

Retrieved on: 
Tuesday, January 2, 2024
Serotonin, Drug development, Research, TAAR1, Brain, Doctor of Philosophy, Human, Element, Assistant, DSM-IV codes, Cell, Nature Communications, Pharmacology, Pharmaceutical industry

NEW YORK, Jan. 2, 2024 /PRNewswire-PRWeb/ -- Researchers at the Icahn School of Medicine at Mount Sinai have uncovered insights into the potential mechanism of action of the antipsychotic medication asenapine, a possible therapeutic target for substance use and neuropsychiatric disorders. This discovery may pave the way for the development of improved medications targeting the same pathway.

Key Points: 
  • This discovery may pave the way for the development of improved medications targeting the same pathway.
  • The study suggests considering species-specific differences in drug-receptor interactions and further investigation into ways asenapine affects the body, as steps toward potential therapeutic improvements.
  • The study suggests considering species-specific differences in drug-receptor interactions and further investigation into ways asenapine affects the body, as steps toward potential therapeutic improvements.
  • "Our findings may guide the development of novel TAAR1 drugs and prompt more exploration of medications similar to asenapine."

Axsome Therapeutics Hosts Solriamfetol Virtual Investor Event with Expert Thought Leaders Today

Retrieved on: 
Thursday, December 7, 2023
Sleep medicine, Psychiatry, Attention deficit hyperactivity disorder, Obstructive sleep apnea, Eastern Time Zone, Division, Binge eating disorder, TAAR1, Psychopharmacology, BED, SHARP, Medical school, DSM-IV codes, MD, Doctor of Philosophy, Research, Therapy, University, HOPE, Associate, EDS, CNS, Narcolepsy, OSA, Webcast, Central nervous system, MDD, Patient, ADHD, Harvard Medical School, Dopamine, SWD

At the event, invited physician thought leaders will discuss current and potential future indications.

Key Points: 
  • At the event, invited physician thought leaders will discuss current and potential future indications.
  • The Axsome senior leadership team will provide an overview of clinical development plans.
  • Expert thought leaders presenting at the event include:
    Craig Chepke, MD, Medical Director of Excel Psychiatric Associates in Huntersville, N.C. and Adjunct Associate Professor of Psychiatry for Atrium Health.
  • A replay of the webcast will be available for approximately 30 days following the live event.

Axsome Therapeutics to Host Solriamfetol Virtual Investor Event on December 7

Retrieved on: 
Wednesday, November 22, 2023
TAAR1, Webcast, Central nervous system, Dopamine, CNS, Therapy

At the event, invited physician thought leaders will discuss current and potential future indications.

Key Points: 
  • At the event, invited physician thought leaders will discuss current and potential future indications.
  • The Axsome senior leadership team will provide an overview of clinical development plans.
  • A live webcast of the event can be accessed on the “Webcasts & Presentations” page of the “Investors” section of the Company’s website at www.axsome.com .
  • A replay of the webcast will be available for approximately 30 days following the live event.

Sunovion and Otsuka Initiate Clinical Development of Ulotaront for the Treatment of Generalized Anxiety Disorder

Retrieved on: 
Wednesday, April 26, 2023
Mental Health, Health, Other Health, Clinical Trials, Pharmaceutical, Biotechnology, GAD, Commercialization, Senior, Sunovion, Ulotaront, Week, Schizophrenia, Anxiety, TAAR1, Multimedia, Appetite, Trial of the century, Sleep, Hamilton Anxiety Rating Scale, Anxiety disorder, DSM-IV codes, MDD, Patient, Mental health, Safety, Pharmaceutical industry, Nursing

Sunovion Pharmaceuticals Inc. (Sunovion) and Otsuka Pharmaceutical Development & Commercialization, Inc. (Otsuka) today announced that the first patient has been randomized in a Phase 2/3 clinical study evaluating ulotaront, a trace amine-associated receptor 1 (TAAR1) agonist with 5-HT1A agonist activity, for the treatment of generalized anxiety disorder (GAD).

Key Points: 
  • Sunovion Pharmaceuticals Inc. (Sunovion) and Otsuka Pharmaceutical Development & Commercialization, Inc. (Otsuka) today announced that the first patient has been randomized in a Phase 2/3 clinical study evaluating ulotaront, a trace amine-associated receptor 1 (TAAR1) agonist with 5-HT1A agonist activity, for the treatment of generalized anxiety disorder (GAD).
  • In addition to GAD, ulotaront is being investigated in late-stage clinical studies for the treatment of schizophrenia and for the adjunctive treatment of major depressive disorder (MDD).
  • “Preliminary data from preclinical and clinical studies of ulotaront suggest an anxiety-reducing effect, which we aim to understand further in patients with GAD.
  • The primary endpoint is reduced anxiety symptoms, as measured by a change from baseline in the Hamilton Anxiety Rating Scale (HAM-A) total score, compared to placebo at Week 8.

Axsome Therapeutics to Present Five Abstracts Including New Data from the Positive SHARP Study of SUNOSI® (solriamfetol) in Participants with Cognitive Impairment with Excessive Daytime Sleepiness in Obstructive Sleep Apnea at the 2023 American Academy of

Retrieved on: 
Friday, April 21, 2023
Abstract, Migraine, Narcolepsy, Central nervous system, University, Obstructive sleep apnea, Somnolence, EDS, AAN, Deficit spending, TAAR1, American Academy, OSA, CNS, Patient, Annual general meeting, Magnetic resonance, Cognitive deficit, Therapy, SHARP, Washington State University, American Academy of Neurology, Pharmaceutical industry, Solriamfetol, Safety

NEW YORK, April 21, 2023 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced that it will be presenting five abstracts at the upcoming 2023 American Academy of Neurology (AAN) Annual Meeting, being held from April 22-27 in Boston.

Key Points: 
  • NEW YORK, April 21, 2023 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced that it will be presenting five abstracts at the upcoming 2023 American Academy of Neurology (AAN) Annual Meeting, being held from April 22-27 in Boston.
  • These presentations include new data from the SHARP study, a randomized, double-blind, placebo-controlled, crossover, multicenter trial in 59 patients with excessive daytime sleepiness (EDS) associated with obstructive sleep apnea (OSA) and impaired cognitive function, from which positive topline results were announced in October 20221.
  • “The SHARP study is exciting because it overcomes treatment barriers associated with the complex relationship between cognitive impairment and OSA,” said Hans Van Dongen, Ph.D., Professor at Washington State University and first author of the SHARP study abstract.
  • “Endpoints from the SHARP study show potential clinical benefit for patients taking solriamfetol versus placebo, suggesting it can be a robust option for the treatment of patients with EDS due to OSA.

Otsuka and Sunovion Initiate Clinical Development of Ulotaront for the Adjunctive Treatment of Major Depressive Disorder

Retrieved on: 
Thursday, December 1, 2022
Mental Health, Health, Other Health, Clinical Trials, General Health, Pharmaceutical, Mental health, Psychiatry, Science, Commercialization, Regulation of tobacco by the U.S. Food and Drug Administration, Global Burden of Disease Study, Sunovion, Grammatical mood, Cardiology, MDD, Algorithm, Patient, Heart, Education, Creativity, Psychology, Maintenance, Medicine, Medication, OAPI, Health, Oncology, Trial of the century, FDA, Food, SUNOVION, Disease, Depression, Tuberculosis, The Lancet, Research, MADRS, TAAR1, Safety, Schizophrenia, Breakthrough therapy, Multimedia, Mood disorder, Investment, Disability, Nephrology, Pharmaceutical industry, Fine chemical

Ulotaront, which is also being evaluated in Phase 3 clinical development for the treatment of schizophrenia, is the first TAAR1 agonist to be studied as an adjunctive therapy in the treatment of MDD.

Key Points: 
  • Ulotaront, which is also being evaluated in Phase 3 clinical development for the treatment of schizophrenia, is the first TAAR1 agonist to be studied as an adjunctive therapy in the treatment of MDD.
  • Ulotaront was granted Breakthrough Therapy Designation by the U.S. Food and Drug Administration (FDA) for the treatment of schizophrenia in 2019.
  • Its also the first TAAR1 agonist to enter into a Phase 2/3 clinical study as an adjunctive therapy for MDD.
  • Major depressive disorder is a chronic debilitating disease characterized by symptoms that last at least two weeks causing significant functional impairment.

Axsome Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update

Retrieved on: 
Monday, November 7, 2022
SG, Migraine, Education, FDA, Omnichannel, Marketing, Research, CNS, Clinical trial, Acquisition, Agitation, R, DDC, NEW, Central nervous system, Company, SHARP, Medicare, Food, Fibromyalgia, Congress, Obstructive sleep apnea, GLOBE, ACCORD, Narcolepsy, Somnolence, Psychiatry, TAAR1, Patient, Efficiency, Dopamine, NMDA, Reboxetine, Smoking, Webcast, New Drug Application, DCC, Breakthrough therapy, Pharmacy, Physician, Primate, Food and Drug Administration, Industry, ADHD, Safety, Medicaid, Therapy, NDA, NASDAQ, AD, Medicare Part D, DSST, MD, SYMPHONY, Medical device, Pharmaceutical industry, Video game, Health insurance, Solriamfetol, COVID-19

Total cost of product sales were $1.9 million for the third quarter of 2022, compared to none for the 2021 comparable period.

Key Points: 
  • Total cost of product sales were $1.9 million for the third quarter of 2022, compared to none for the 2021 comparable period.
  • Research and development (R&D) expenses were $14.9 million for the third quarter of 2022 and $13.2 million for the comparable period in 2021.
  • Third quarter U.S. Sunosi total prescriptions increased by 15% versus the third quarter of 2021, and by 3% versus the second quarter of 2022.
  • Axsome announced the commercial launch of Auvelity on October 20, 2022, following its approval by the FDA on August 18, 2022.

Sunovion, Sumitomo Dainippon Pharma and Otsuka Enter Worldwide Development and Commercialization Collaboration

Retrieved on: 
Thursday, September 30, 2021
Mental Health, Health, Managed Care, Clinical Trials, Pharmaceutical, Biotechnology, Lists of diseases, Regulation of tobacco by the U.S. Food and Drug Administration, Neuropsychiatry, Program, Growth, Pharmacology, Creativity, Psychology, Investment, Bipolar I disorder, Sumitomo Dainippon Pharma, Food, Amisulpride, Health, Mental disorder, Commercialization, Depression, Multimedia, LinkedIn, Heart, Twitter, Medicine, Science, Facebook, Maintenance, Global Burden of Disease Study, Dementia, Internet, USD, Solution, FDA, Neurology, World Health Organization, YouTube, Â, Disease burden, Brain, Agitation, TAAR1, Education, Tuberculosis, SUNOVION, WHO, Patient, Sunovion, Algorithm, Psychiatry, Research, Schizophrenia, Fine chemical, Pharmaceutical industry, Sunovion Compounds, Neuropsychiatric Disorders, Sunovion, Sumitomo Dainippon Pharma, SUNOVION COMPOUNDS, NEUROPSYCHIATRIC DISORDERS, SUNOVION, SUMITOMO DAINIPPON PHARMA

Sunovion Pharmaceuticals Inc. (Sunovion),its parent company Sumitomo Dainippon Pharma Co., Ltd. (Sumitomo Dainippon Pharma) and Otsuka Pharmaceutical Co., Ltd. (Otsuka) announced today that the companies have entered into a worldwide license agreement for the joint development and commercialization of four compounds: ulotaront (SEP-363856), non-racemic ratio of amisulpride enantiomers (SEP-4199), SEP-378614 and SEP-380135.

Key Points: 
  • Sunovion Pharmaceuticals Inc. (Sunovion),its parent company Sumitomo Dainippon Pharma Co., Ltd. (Sumitomo Dainippon Pharma) and Otsuka Pharmaceutical Co., Ltd. (Otsuka) announced today that the companies have entered into a worldwide license agreement for the joint development and commercialization of four compounds: ulotaront (SEP-363856), non-racemic ratio of amisulpride enantiomers (SEP-4199), SEP-378614 and SEP-380135.
  • Sumitomo Dainippon Pharma aims to achieve sustained growth through global collaboration in anticipation of future changes in the business environment.
  • Sumitomo Dainippon Pharma is based on the merger in 2005 between Dainippon Pharmaceutical Co., Ltd., and Sumitomo Pharmaceuticals Co., Ltd. Today, Sumitomo Dainippon Pharma has more than 7,000 employees worldwide.
  • SUNOVION is a registered trademark of Sumitomo Dainippon Pharma Co., Ltd.
    Sunovion Pharmaceuticals Inc. is a U.S. subsidiary of Sumitomo Dainippon Pharma Co., Ltd.
    2021 Sunovion Pharmaceuticals Inc. All rights reserved.

Schizophrenia Drug Pipeline Market Research Report 2021 - ResearchAndMarkets.com

Retrieved on: 
Thursday, August 5, 2021
Pharmaceutical, Health, Mental Health, TAAR1, M1, Teva Pharmaceuticals, CYP2D6, United States, Brain, Dnata Singapore, Route, Boehringer Ingelheim, Administration, Therapy, Route of administration, Patient, US Foods, Merck Sharp & Dohme Federal Credit Union, Agonist, Government budget balance, Biotinidase, M4, N-Methyl-D-aspartic acid, Hallucination, Intention, Cognition, Food and Drug Administration, Alzheimer's disease, 5-HT2A receptor, Deuterium, Agitation, Delusion, PDE10A, NDA, Breakthrough therapy, Psychosis, Food, Movement disorders, Risperidone, Pharmaceutical industry, Medical device

The "Schizophrenia - Pipeline Insight, 2021" clinical trials has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Schizophrenia - Pipeline Insight, 2021" clinical trials has been added to ResearchAndMarkets.com's offering.
  • This Schizophrenia - Pipeline Insight, 2021 provides comprehensive insights about 70+ companies and 70+ pipeline drugs in Schizophrenia pipeline landscape.
  • The companies which have their Schizophrenia drug candidates in the most advanced stage, i.e.
  • Schizophrenia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.